Danaher Corporation (DAP.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
At close: 05:35PM CEST
| Previous close | 243.05 |
| Open | 244.95 |
| Bid | 243.30 x N/A |
| Ask | 243.80 x N/A |
| Day's range | 243.35 - 245.30 |
| 52-week range | 172.40 - 245.30 |
| Volume | |
| Avg. volume | 545 |
| Market cap | 181.16B |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | 48.56 |
| EPS (TTM) | 5.02 |
| Earnings date | 23 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | 1.00 (0.41%) |
| Ex-dividend date | 28 Jun 2024 |
| 1y target est | N/A |
GuruFocus.comInsider Sale: President & CEO Rainer Blair Sells 9,005 Shares of Danaher Corp (DHR)
On May 16, 2024, Rainer Blair, President & CEO of Danaher Corp (NYSE:DHR), executed a sale of 9,005 shares of the company.
ZacksDanaher (DHR) Rides on Business Strength Amid Headwinds
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
The TelegraphQuestor: This biotech giant is backed by the world’s best fund managers
Remember Abcam? The Cambridge-based biotech was a darling of the Aim market until it decided in late-2022 to abandon London in favour of a listing on the US exchange Nasdaq.
© 2024 Yahoo. All rights reserved.